Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland
- DOI
- 10.3390/cancers14051218
- Published
- 2022-02-26
- Container
- Cancers
- Publisher
- MDPI AG
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3390/cancers14051218,
title = {Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland},
author = {Agnieszka Irena Jagiełło-Gruszfeld and Magdalena Rosinska and Małgorzata Meluch and Katarzyna Pogoda and Anna Niwinska and Renata Sienkiewicz and Aleksander Grous and Paweł Winter and Zbigniew I. Nowecki},
year = {2022},
journal = {Cancers},
doi = {10.3390/cancers14051218},
url = {https://doi.org/10.3390/cancers14051218}
}RIS
TY - JOUR TI - Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland AU - Agnieszka Irena Jagiełło-Gruszfeld AU - Magdalena Rosinska AU - Małgorzata Meluch AU - Katarzyna Pogoda AU - Anna Niwinska AU - Renata Sienkiewicz AU - Aleksander Grous AU - Paweł Winter AU - Zbigniew I. Nowecki PY - 2022 JO - Cancers DO - 10.3390/cancers14051218 UR - https://doi.org/10.3390/cancers14051218 ER -
APA
Jagiełło-Gruszfeld, A. I., Rosinska, M., Meluch, M., Pogoda, K., Niwinska, A., Sienkiewicz, R., Grous, A., Winter, P., & Nowecki, Z. I. (2022). Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers. https://doi.org/10.3390/cancers14051218
Source records
- crossref · retrieved 2026-09-27T15:56:27.451Z